Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
NASDAQ:ASND
Price:
135.76 USD
0.49%
Market Closed
Updated:
Jun 3, 2024
Ascendis Pharma A/S
Stock-Based Compensation
|
Ascendis Pharma A/S
Stock-Based Compensation Peer Comparison
Comparables:
GMAB
ZEAL
B
BAVA
BIOPOR
SANION
Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Stock-Based Compensation
€70.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Ascendis Pharma A/S's Stock-Based Compensation?
Stock-Based Compensation
70.3m
EUR
70.3m
EUR
Based on the financial report for Mar 31, 2024, Ascendis Pharma A/S's Stock-Based Compensation amounts to 70.3m EUR.
What is Ascendis Pharma A/S's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
24%
24%
Over the last year, the Stock-Based Compensation growth was 21%. The average annual Stock-Based Compensation growth rates for Ascendis Pharma A/S have been 5% over the past three years , 24% over the past five years .
You don't have any saved screeners yet
